---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-009006"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2024-03-05T23:59:59+00:00"
generated_at: "2026-06-05T03:21:53.065222+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cumberland Pharma reports 2023 net loss of $6.3M; revenue $40M; Caldolor labeling expanded to infants

## Summary
- Net loss $6.3M for 2023, includes $3.3M non-cash charge on product discontinuation; adjusted earnings $2.4M ($0.17/share).
- Revenue $40M from four brands: Kristalose $16M, Vibativ $8.8M, Sancuso $8.1M, Caldolor $4.3M.
- FDA approved expanded Caldolor labeling for infants 3-6 months; only non-opioid injectable for pain/fever in that age group.
- NOPAIN Act expected to provide favorable CMS reimbursement for Caldolor starting 2025; company submitted request.
- Ifetroban Phase II trials ongoing for DMD, scleroderma, IPF; FDA grants >$1M; oral capsule study initiated.

## SEC filing metadata
- accession: 0001628280-24-009006
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2024-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828024009006/0001628280-24-009006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828024009006/cpix-20240305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-009006
- JSON: https://secwatch.observer/filing/0001628280-24-009006.json
- Plain text: https://secwatch.observer/filing/0001628280-24-009006.txt

## Key facts
- Earnings Releases
  CUMBERLAND PHARMACEUTICALS INC reported financial results for the year ended December 31, 2023.
  - Period: the year ended December 31, 2023
  - Result: reported results
  source text: On March 5, 2024, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release which provided a company update and the financial results for the three months and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1087294/000162828024009006/0001628280-24-009006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.